A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Martin H. Voss; A. Hussain; N. Vogelzang; J. L. Lee; B. Keam; S. Y. Rha; U. Vaishampayan; W. B. Harris; S. Richey; J. M. Randall; D. Shaffer; A. Cohn; T. Crowell; J. Li; A. Senderowicz; E. Stone; R. Figlin; R. J. Motzer; N. B. Haas; T. Hutson

doi:10.1093/annonc/mdx493

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Martin H. Voss, A. Hussain, N. Vogelzang, J. L. Lee, B. Keam, S. Y. Rha, U. Vaishampayan, W. B. Harris, S. Richey, J. M. Randall, D. Shaffer, A. Cohn, T. Crowell, J. Li, A. Senderowicz, E. Stone, R. Figlin, R. J. Motzer, N. B. Haas, T. Hutson

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Background: Nanoparticle-drug conjugates enhance drug delivery to tumors. Gradual payload release inside cancer cells augments antitumor activity while reducing toxicity. CRLX101 is a novel nanoparticle-drug conjugate containing camptothecin, a potent inhibitor of topoisomerase I and the hypoxia-inducible factors 1α and 2α. In a phase Ib/2 trial, CRLX101+bevacizumab was well tolerated with encouraging activity in metastatic renal cell carcinoma (mRCC). We conducted a randomized phase II trial comparing CRLX101+bevacizumab versus standard of care (SOC) in refractory mRCC. Patients and methods: Patients with mRCC and 2-3 prior lines of therapy were randomized 1: 1 to CRLX101+bevacizumab versus SOC, defined as investigator's choice of any approved regimen not previously received. The primary end point was progression-free survival (PFS) by blinded independent radiological review in patients with clear cell mRCC. Secondary end points included overall survival, objective response rate and safety. Results: In total, 111 patients were randomized and received ≥ 1 dose of drug (CRLX101+bevacizumab, 55; SOC, 56). Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2). In the clear cell population, the median PFS on the CRLX101+bevacizumab and SOC arms was 3.7 months (95% confidence interval, 2.0-4.3) and 3.9 months (95% confidence interval 2.2-5.4), respectively (stratified log-rank P = 0 .831). The objective response rate by IRR was 5% with CRLX101+bevacizumab versus 14% with SOC (Mantel-Haenszel test, P = 0.836). Consistent with previous studies, the CRLX101+bevacizumab combination was generally well tolerated, and no new safety signal was identified. Conclusions: Despite promising efficacy data on the earlier phase Ib/2 trial of mRCC, this randomized trial did not demonstrate improvement in PFS for the CRLX101+bevacizumab combination when compared with approved agents in patients with heavily pretreated clear cell mRCC. Further development in this disease is not planned.

Original language	English
Pages (from-to)	2754-2760
Number of pages	7
Journal	Annals of Oncology
Volume	28
Issue number	11
DOIs	https://doi.org/10.1093/annonc/mdx493
Publication status	Published - 2017 Nov

Bibliographical note

Funding Information:
This trial was supported by Cerulean Pharmaceuticals (no grant number applies).

Funding Information:
Patients treated at Memorial Sloan Kettering Cancer Center were supported in part by Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748).

Funding Information:
MHV reports consulting/advisory role for Eisai, Exelixis, Novartis, Pfizer and has received research support from Roche/ Genentech and BMS. AH reports consulting/advisory role for Novartis and BMS. NV reports speaking engagements for BMS, Exelixis, and Roche/Genentech; consulting/advisory role for Norvartis, Pfizer, and Cerulean. JLL reports consulting/advisory role for AstraZeneca and Astellas and honoraria for AstraZeneca, Astellas, and Pfizer. UNV reports consulting/advisory role for Genentech, BMS, Exelixis, Novartis, Pfizer and has received research support from Novartis and BMS. SR reports consulting/ advisory role for Exelixis, Pfizer, Prometheus, and Sanofi and has received research funding from Novartis, BMS, Eisai, Genentech/ Roche, GSK, and Abbvie. AC reports consulting for BMS, Roche/ Genentech and speaker bureau for Merrimack. RJM reports consulting/advisory role for Pfizer, Novartis, Eisai, Exelixis and has received research support from BMS, Pfizer, Genentech/Roche, Eisai, Exelixis, and Novartis. NBH reports consulting/advisory role for Cerulean Pharmaceuticals, Novartis, and Exelixis. TH reports consulting/advisory role and has received research support for Pfizer, Novartis, Roche/Genentech, BMS, AVEO, Eisai, and Exelixis. The following authors are employees of Cerulean Pharmaceuticals: TC, JL, AS, and ES. All remaining authors have declared no conflicts of interest.

Publisher Copyright:
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

All Science Journal Classification (ASJC) codes

Hematology
Oncology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1093/annonc/mdx493

Fingerprint Dive into the research topics of 'A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma'. Together they form a unique fingerprint.

Cite this

Voss, M. H., Hussain, A., Vogelzang, N., Lee, J. L., Keam, B., Rha, S. Y., Vaishampayan, U., Harris, W. B., Richey, S., Randall, J. M., Shaffer, D., Cohn, A., Crowell, T., Li, J., Senderowicz, A., Stone, E., Figlin, R., Motzer, R. J., Haas, N. B., & Hutson, T. (2017). A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. Annals of Oncology, 28(11), 2754-2760. https://doi.org/10.1093/annonc/mdx493

Voss, Martin H. ; Hussain, A. ; Vogelzang, N. ; Lee, J. L. ; Keam, B. ; Rha, S. Y. ; Vaishampayan, U. ; Harris, W. B. ; Richey, S. ; Randall, J. M. ; Shaffer, D. ; Cohn, A. ; Crowell, T. ; Li, J. ; Senderowicz, A. ; Stone, E. ; Figlin, R. ; Motzer, R. J. ; Haas, N. B. ; Hutson, T. / A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. In: Annals of Oncology. 2017 ; Vol. 28, No. 11. pp. 2754-2760.

@article{7dfe7567760544df982c0b47b289c8b5,

title = "A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma",

abstract = "Background: Nanoparticle-drug conjugates enhance drug delivery to tumors. Gradual payload release inside cancer cells augments antitumor activity while reducing toxicity. CRLX101 is a novel nanoparticle-drug conjugate containing camptothecin, a potent inhibitor of topoisomerase I and the hypoxia-inducible factors 1α and 2α. In a phase Ib/2 trial, CRLX101+bevacizumab was well tolerated with encouraging activity in metastatic renal cell carcinoma (mRCC). We conducted a randomized phase II trial comparing CRLX101+bevacizumab versus standard of care (SOC) in refractory mRCC. Patients and methods: Patients with mRCC and 2-3 prior lines of therapy were randomized 1: 1 to CRLX101+bevacizumab versus SOC, defined as investigator's choice of any approved regimen not previously received. The primary end point was progression-free survival (PFS) by blinded independent radiological review in patients with clear cell mRCC. Secondary end points included overall survival, objective response rate and safety. Results: In total, 111 patients were randomized and received ≥ 1 dose of drug (CRLX101+bevacizumab, 55; SOC, 56). Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2). In the clear cell population, the median PFS on the CRLX101+bevacizumab and SOC arms was 3.7 months (95% confidence interval, 2.0-4.3) and 3.9 months (95% confidence interval 2.2-5.4), respectively (stratified log-rank P = 0 .831). The objective response rate by IRR was 5% with CRLX101+bevacizumab versus 14% with SOC (Mantel-Haenszel test, P = 0.836). Consistent with previous studies, the CRLX101+bevacizumab combination was generally well tolerated, and no new safety signal was identified. Conclusions: Despite promising efficacy data on the earlier phase Ib/2 trial of mRCC, this randomized trial did not demonstrate improvement in PFS for the CRLX101+bevacizumab combination when compared with approved agents in patients with heavily pretreated clear cell mRCC. Further development in this disease is not planned.",

author = "Voss, {Martin H.} and A. Hussain and N. Vogelzang and Lee, {J. L.} and B. Keam and Rha, {S. Y.} and U. Vaishampayan and Harris, {W. B.} and S. Richey and Randall, {J. M.} and D. Shaffer and A. Cohn and T. Crowell and J. Li and A. Senderowicz and E. Stone and R. Figlin and Motzer, {R. J.} and Haas, {N. B.} and T. Hutson",

note = "Funding Information: This trial was supported by Cerulean Pharmaceuticals (no grant number applies). Funding Information: Patients treated at Memorial Sloan Kettering Cancer Center were supported in part by Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). Funding Information: MHV reports consulting/advisory role for Eisai, Exelixis, Novartis, Pfizer and has received research support from Roche/ Genentech and BMS. AH reports consulting/advisory role for Novartis and BMS. NV reports speaking engagements for BMS, Exelixis, and Roche/Genentech; consulting/advisory role for Norvartis, Pfizer, and Cerulean. JLL reports consulting/advisory role for AstraZeneca and Astellas and honoraria for AstraZeneca, Astellas, and Pfizer. UNV reports consulting/advisory role for Genentech, BMS, Exelixis, Novartis, Pfizer and has received research support from Novartis and BMS. SR reports consulting/ advisory role for Exelixis, Pfizer, Prometheus, and Sanofi and has received research funding from Novartis, BMS, Eisai, Genentech/ Roche, GSK, and Abbvie. AC reports consulting for BMS, Roche/ Genentech and speaker bureau for Merrimack. RJM reports consulting/advisory role for Pfizer, Novartis, Eisai, Exelixis and has received research support from BMS, Pfizer, Genentech/Roche, Eisai, Exelixis, and Novartis. NBH reports consulting/advisory role for Cerulean Pharmaceuticals, Novartis, and Exelixis. TH reports consulting/advisory role and has received research support for Pfizer, Novartis, Roche/Genentech, BMS, AVEO, Eisai, and Exelixis. The following authors are employees of Cerulean Pharmaceuticals: TC, JL, AS, and ES. All remaining authors have declared no conflicts of interest. Publisher Copyright: {\textcopyright} The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.",

year = "2017",

month = nov,

doi = "10.1093/annonc/mdx493",

language = "English",

volume = "28",

pages = "2754--2760",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "11",

}

Voss, MH, Hussain, A, Vogelzang, N, Lee, JL, Keam, B, Rha, SY, Vaishampayan, U, Harris, WB, Richey, S, Randall, JM, Shaffer, D, Cohn, A, Crowell, T, Li, J, Senderowicz, A, Stone, E, Figlin, R, Motzer, RJ, Haas, NB & Hutson, T 2017, 'A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma', Annals of Oncology, vol. 28, no. 11, pp. 2754-2760. https://doi.org/10.1093/annonc/mdx493

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. / Voss, Martin H.; Hussain, A.; Vogelzang, N.; Lee, J. L.; Keam, B.; Rha, S. Y.; Vaishampayan, U.; Harris, W. B.; Richey, S.; Randall, J. M.; Shaffer, D.; Cohn, A.; Crowell, T.; Li, J.; Senderowicz, A.; Stone, E.; Figlin, R.; Motzer, R. J.; Haas, N. B.; Hutson, T.

In: Annals of Oncology, Vol. 28, No. 11, 11.2017, p. 2754-2760.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

AU - Voss, Martin H.

AU - Hussain, A.

AU - Vogelzang, N.

AU - Lee, J. L.

AU - Keam, B.

AU - Rha, S. Y.

AU - Vaishampayan, U.

AU - Harris, W. B.

AU - Richey, S.

AU - Randall, J. M.

AU - Shaffer, D.

AU - Cohn, A.

AU - Crowell, T.

AU - Li, J.

AU - Senderowicz, A.

AU - Stone, E.

AU - Figlin, R.

AU - Motzer, R. J.

AU - Haas, N. B.

AU - Hutson, T.

N1 - Funding Information: This trial was supported by Cerulean Pharmaceuticals (no grant number applies). Funding Information: Patients treated at Memorial Sloan Kettering Cancer Center were supported in part by Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). Funding Information: MHV reports consulting/advisory role for Eisai, Exelixis, Novartis, Pfizer and has received research support from Roche/ Genentech and BMS. AH reports consulting/advisory role for Novartis and BMS. NV reports speaking engagements for BMS, Exelixis, and Roche/Genentech; consulting/advisory role for Norvartis, Pfizer, and Cerulean. JLL reports consulting/advisory role for AstraZeneca and Astellas and honoraria for AstraZeneca, Astellas, and Pfizer. UNV reports consulting/advisory role for Genentech, BMS, Exelixis, Novartis, Pfizer and has received research support from Novartis and BMS. SR reports consulting/ advisory role for Exelixis, Pfizer, Prometheus, and Sanofi and has received research funding from Novartis, BMS, Eisai, Genentech/ Roche, GSK, and Abbvie. AC reports consulting for BMS, Roche/ Genentech and speaker bureau for Merrimack. RJM reports consulting/advisory role for Pfizer, Novartis, Eisai, Exelixis and has received research support from BMS, Pfizer, Genentech/Roche, Eisai, Exelixis, and Novartis. NBH reports consulting/advisory role for Cerulean Pharmaceuticals, Novartis, and Exelixis. TH reports consulting/advisory role and has received research support for Pfizer, Novartis, Roche/Genentech, BMS, AVEO, Eisai, and Exelixis. The following authors are employees of Cerulean Pharmaceuticals: TC, JL, AS, and ES. All remaining authors have declared no conflicts of interest. Publisher Copyright: © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

PY - 2017/11

Y1 - 2017/11

N2 - Background: Nanoparticle-drug conjugates enhance drug delivery to tumors. Gradual payload release inside cancer cells augments antitumor activity while reducing toxicity. CRLX101 is a novel nanoparticle-drug conjugate containing camptothecin, a potent inhibitor of topoisomerase I and the hypoxia-inducible factors 1α and 2α. In a phase Ib/2 trial, CRLX101+bevacizumab was well tolerated with encouraging activity in metastatic renal cell carcinoma (mRCC). We conducted a randomized phase II trial comparing CRLX101+bevacizumab versus standard of care (SOC) in refractory mRCC. Patients and methods: Patients with mRCC and 2-3 prior lines of therapy were randomized 1: 1 to CRLX101+bevacizumab versus SOC, defined as investigator's choice of any approved regimen not previously received. The primary end point was progression-free survival (PFS) by blinded independent radiological review in patients with clear cell mRCC. Secondary end points included overall survival, objective response rate and safety. Results: In total, 111 patients were randomized and received ≥ 1 dose of drug (CRLX101+bevacizumab, 55; SOC, 56). Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2). In the clear cell population, the median PFS on the CRLX101+bevacizumab and SOC arms was 3.7 months (95% confidence interval, 2.0-4.3) and 3.9 months (95% confidence interval 2.2-5.4), respectively (stratified log-rank P = 0 .831). The objective response rate by IRR was 5% with CRLX101+bevacizumab versus 14% with SOC (Mantel-Haenszel test, P = 0.836). Consistent with previous studies, the CRLX101+bevacizumab combination was generally well tolerated, and no new safety signal was identified. Conclusions: Despite promising efficacy data on the earlier phase Ib/2 trial of mRCC, this randomized trial did not demonstrate improvement in PFS for the CRLX101+bevacizumab combination when compared with approved agents in patients with heavily pretreated clear cell mRCC. Further development in this disease is not planned.

AB - Background: Nanoparticle-drug conjugates enhance drug delivery to tumors. Gradual payload release inside cancer cells augments antitumor activity while reducing toxicity. CRLX101 is a novel nanoparticle-drug conjugate containing camptothecin, a potent inhibitor of topoisomerase I and the hypoxia-inducible factors 1α and 2α. In a phase Ib/2 trial, CRLX101+bevacizumab was well tolerated with encouraging activity in metastatic renal cell carcinoma (mRCC). We conducted a randomized phase II trial comparing CRLX101+bevacizumab versus standard of care (SOC) in refractory mRCC. Patients and methods: Patients with mRCC and 2-3 prior lines of therapy were randomized 1: 1 to CRLX101+bevacizumab versus SOC, defined as investigator's choice of any approved regimen not previously received. The primary end point was progression-free survival (PFS) by blinded independent radiological review in patients with clear cell mRCC. Secondary end points included overall survival, objective response rate and safety. Results: In total, 111 patients were randomized and received ≥ 1 dose of drug (CRLX101+bevacizumab, 55; SOC, 56). Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2). In the clear cell population, the median PFS on the CRLX101+bevacizumab and SOC arms was 3.7 months (95% confidence interval, 2.0-4.3) and 3.9 months (95% confidence interval 2.2-5.4), respectively (stratified log-rank P = 0 .831). The objective response rate by IRR was 5% with CRLX101+bevacizumab versus 14% with SOC (Mantel-Haenszel test, P = 0.836). Consistent with previous studies, the CRLX101+bevacizumab combination was generally well tolerated, and no new safety signal was identified. Conclusions: Despite promising efficacy data on the earlier phase Ib/2 trial of mRCC, this randomized trial did not demonstrate improvement in PFS for the CRLX101+bevacizumab combination when compared with approved agents in patients with heavily pretreated clear cell mRCC. Further development in this disease is not planned.

UR - http://www.scopus.com/inward/record.url?scp=85034025597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034025597&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx493

DO - 10.1093/annonc/mdx493

M3 - Article

C2 - 28950297

AN - SCOPUS:85034025597

VL - 28

SP - 2754

EP - 2760

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this